DiaSys enters Chinese market via Vastec Medical deal:
This article was originally published in Clinica
Executive Summary
DiaSys has signed a three-year exclusive agreement with Vastec Medical, a Hong Kong and China-based medical products distribution company. Under the terms of the agreement, Vastec will distribute and service DiaSys' urine sediment workstations throughout China and Hong Kong. The deal, which initially provides for a minimum order of 36 workstations, also gives Vastec first refusal to distribute future DiaSys products in China and Hong Kong. Vastec's managing director K S Ho says laboratory operating costs are making urine sediment analysis a difficult test to justify in China and Hong Kong. DiaSys' R/S series workstations provide standardisation and automation at affordable prices, Mr Ho adds.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.